[go: up one dir, main page]

NO20060081L - Pyrrol-2,5-dionderivater som lever X reseptormodulatorer - Google Patents

Pyrrol-2,5-dionderivater som lever X reseptormodulatorer

Info

Publication number
NO20060081L
NO20060081L NO20060081A NO20060081A NO20060081L NO 20060081 L NO20060081 L NO 20060081L NO 20060081 A NO20060081 A NO 20060081A NO 20060081 A NO20060081 A NO 20060081A NO 20060081 L NO20060081 L NO 20060081L
Authority
NO
Norway
Prior art keywords
pyrrole
supplying
receptor modulators
dione derivatives
methods
Prior art date
Application number
NO20060081A
Other languages
English (en)
Inventor
Christer Westerlund
Pernilla Marie Sandberg
Kay Brickmann
Patrik Holm
Jonas Bostrom
Marianne Swanson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060081L publication Critical patent/NO20060081L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår visse nye forbindelser med formel I. fremgangsmåter for fremstilling av slike forbindelser, anvendelse av dem ved modulering av nukleære hormonreseptorer Lever X Reseptor (LXR) a (NR1H3) og/eller p (NR1H2) og ved behandling og/eller forhindring av kliniske lidelser omfattende kardiovaskulære sykdommer, så som aterosklerose; inflammatoriske sykdommer, Alzheimers sykdom, lipidforstyrrelser (dyslipidemier), enten de er forbundet med insulinresistens eller ikke, type 2 diabetes og andre manifestasjoner av det metabolske syndrom, metoder for terapeutisk anvendelse av dem, og farmasøytiske preparater inneholdende dem.
NO20060081A 2003-07-11 2006-01-05 Pyrrol-2,5-dionderivater som lever X reseptormodulatorer NO20060081L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001114 WO2005005417A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators

Publications (1)

Publication Number Publication Date
NO20060081L true NO20060081L (no) 2006-02-08

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060081A NO20060081L (no) 2003-07-11 2006-01-05 Pyrrol-2,5-dionderivater som lever X reseptormodulatorer

Country Status (25)

Country Link
US (1) US7432288B2 (no)
EP (1) EP1646626B1 (no)
JP (1) JP2007521312A (no)
KR (1) KR20060035748A (no)
CN (1) CN1823061A (no)
AR (1) AR045721A1 (no)
AT (1) ATE399777T1 (no)
AU (1) AU2004255999B2 (no)
BR (1) BRPI0412472A (no)
CA (1) CA2532056A1 (no)
DE (1) DE602004014773D1 (no)
ES (1) ES2308204T3 (no)
GB (1) GB0316232D0 (no)
IL (1) IL172760A0 (no)
IS (1) IS8293A (no)
MX (1) MXPA06000414A (no)
MY (1) MY135821A (no)
NO (1) NO20060081L (no)
RU (1) RU2006102130A (no)
SA (1) SA04250204B1 (no)
TW (1) TW200503691A (no)
UA (1) UA82109C2 (no)
UY (1) UY28408A1 (no)
WO (1) WO2005005417A1 (no)
ZA (1) ZA200600222B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634877B1 (en) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of antrodia camphorata and use thereof
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
KR20070094963A (ko) 2005-01-10 2007-09-27 아스트라제네카 아베 간 ｘ 수용체 조절제로서 이소티아졸-3(2ｈ)-온1,1-디옥사이드 유도체
JP2009535315A (ja) * 2006-04-28 2009-10-01 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 二環式テトラヒドロピロール化合物
CA2660963A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
WO2010003025A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
BR112013005425A2 (pt) 2010-09-07 2018-05-02 Snu R&Db Foundation compostos sesterterpenos e suas utilizações
BR112013013649A2 (pt) 2010-12-03 2016-09-06 Allergan Inc derivados de oxima azetidina como moduladores de receptor de esfingosina 1-fosfato (s1p)
CN103370102A (zh) 2010-12-03 2013-10-23 阿勒根公司 作为鞘氨醇1-磷酸(s1p)受体调节的新型肟衍生物
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
MX2022007164A (es) 2019-12-13 2022-09-12 Inspirna Inc Sales metálicas y usos de estas.
US11753374B2 (en) * 2020-11-18 2023-09-12 Southern Reserach Institute Compounds for the treatment of acute and chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141080A0 (en) 1998-07-30 2002-02-10 Japan Tobacco Inc Disubstituted maleimide derivatives and pharmaceutical compositions containing the same
ATE284387T1 (de) 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
WO2001013916A1 (en) 1999-08-20 2001-03-01 Sagami Chemical Research Center Drugs inhibiting cell death
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
KR20060035748A (ko) 2006-04-26
CA2532056A1 (en) 2005-01-20
AU2004255999B2 (en) 2007-08-02
GB0316232D0 (en) 2003-08-13
AU2004255999A1 (en) 2005-01-20
RU2006102130A (ru) 2007-08-20
EP1646626B1 (en) 2008-07-02
UA82109C2 (uk) 2008-03-11
IS8293A (is) 2006-02-09
WO2005005417A1 (en) 2005-01-20
CN1823061A (zh) 2006-08-23
SA04250204B1 (ar) 2008-03-23
MXPA06000414A (es) 2006-03-17
DE602004014773D1 (de) 2008-08-14
ZA200600222B (en) 2007-04-25
HK1088320A1 (en) 2006-11-03
US20060235015A1 (en) 2006-10-19
IL172760A0 (en) 2006-04-10
UY28408A1 (es) 2005-02-28
EP1646626A1 (en) 2006-04-19
JP2007521312A (ja) 2007-08-02
MY135821A (en) 2008-07-31
ES2308204T3 (es) 2008-12-01
US7432288B2 (en) 2008-10-07
ATE399777T1 (de) 2008-07-15
TW200503691A (en) 2005-02-01
AR045721A1 (es) 2005-11-09
BRPI0412472A (pt) 2006-09-19

Similar Documents

Publication Publication Date Title
NO20060081L (no) Pyrrol-2,5-dionderivater som lever X reseptormodulatorer
NO20060080L (no) Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer
NO20073250L (no) Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.
WO2007050726A3 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
NO20055892L (no) Karboksylsyrederivater
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
WO2009009501A3 (en) Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2006022428A1 (ja) 糖尿病治療剤
WO2004052847A3 (en) Tricyclic steroid hormone nuclear receptor modulators
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
NO20073248L (no) Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
Jordan et al. Newly developed dopamine D3 receptor antagonists, R-VK4-40 and R-VK4-116, do not potentiate cardiovascular effects of cocaine or oxycodone in rats
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
TW200526216A (en) Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and-or to obesity
EP1435353A1 (en) Novel heterocyclic compound and anti-inflammatory agent
NO20065501L (no) Lxr reseptor modulstorer.
TWI676624B (zh) 新穎化合物
CN109906222A (zh) 减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂
EP2412705B1 (en) Novel therapeutic agent for cognitive impairment
Ma et al. Straightforward and effective synthesis of γ-aminobutyric acid transporter subtype 2-selective acyl-substituted azaspiro [4.5] decanes
SE0500056D0 (sv) Therapeutic agents 4
CN101663035A (zh) 4－环丙基甲氧基－n－(3,5－二氯代－1－环氧－吡啶－4－基)－5－(甲氧基)吡啶－2－甲酰胺用于治疗与帕金森症有关的运动障碍的用途
SE0500058D0 (sv) Therapeutic agents 5

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application